Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameFusen Pharm
Stock Code01652
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities從事研發、生產及銷售多種用以治療感冒及發熱、心血管疾病及貧血的中成藥及西藥產品,核心產品為雙黃連類感冒藥。
Listing Date2018-07-11
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)河南省淅川縣城區工業園區
Business Address (Hong Kong)香港灣仔告士打道56號東亞銀行港灣中心29樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.fusenyy.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 2.08 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.01 / shares
Offer Period2018-06-28 to 2018-07-04
Global Offering Shares200,000,000 shares
HK Public Offer Shares (Initial)20,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)180,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO800,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 416,000,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 704.9M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +1278%

Valuation & Financials

Market Cap (at Offer Price)HK$ 2,000,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣97.1百萬元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 45,600,000
Listing Expenses / Funds Raised~10.96%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201520162017
Revenue 368,634441,988452,580
Cost of sales -195,357-219,799-200,634
Gross profit 173,277222,189251,946
Other income and gains, net 3,25110,8885,918
Selling and distribution expenses -63,636-74,208-90,704
Administrative expenses -26,039-40,277-44,980
Operating profit 86,853118,592122,180
Net finance costs -29,585-3,824-5,844
Profit before tax 57,268114,768116,336
Income tax expense -11,233-18,570-19,285
Profit for the year 46,03596,19897,051
Profit attributable to owners 44,87995,07396,820
Balance Sheet
Item 201520162017
Cash and cash equivalents 32,569244,390474,621
Trade and bills receivables 208,800123,027109,115
Inventories 106,633100,779100,506
Total current assets 1,156,165944,910752,749
Total assets 1,361,4771,151,088951,220
Total current liabilities 1,016,807994,628731,978
Total liabilities 1,167,2821,024,479768,443
Total equity 194,195126,609182,777
Equity attributable to owners 189,583121,065180,565
Interest-bearing borrowings 766,262600,678391,600
Cash Flow Statement
Item 201520162017
Net cash from operating activities 69,804172,345133,206
Net cash from investing activities 67,185327,666455,514
Net cash from financing activities -131,625-288,190-358,370
Net increase in cash 5,364211,821230,350
Depreciation of PP&E 14,94615,04515,996
Amortisation of intangible assets 117200200
Purchase of PP&E -27,837-19,977-4,410
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 2.54
First Day OpenHK$ 2.33
First Day Change22.12%
First Day Volume72934000.0
First Day Turnover180523000.0
Use of Proceeds
1、約30%或112.4百萬港元將用于擴充計劃; 2、約10%或37.4百萬港元將用于產品廣告及營銷; 3、約10%或37.4百萬港元將用于擴展現有營銷及分銷網絡,以提高市場滲透水平,覆蓋更多最終客戶,從而增加市場占有率; 4、約10%或37.4百萬港元將用于繼續進行研究及開發活動,尤其是為與外部合作伙伴合作進行的研究項目提供資金; 5、約15%或56.1百萬港元將用于并購治療領域與我們目前重點治療領域類似的中成藥飲片及顆粒劑或其他西藥生產商,以拓展產品組合及增強競爭優勢; 6、約15%或56.1百萬港元將用作收購中成藥或其他西藥的生產許可證,以拓展產品組合; 7、約10%或約37.4百萬港元將用于為營運資金及其他一般企業用途提供資金。

Underwriting Syndicate

Sole Sponsor (1)
中信建投(国际)融资有限公司 CE BAU112
Overall Coordinators (3)
中信建投(国际)融资有限公司 CE BAU112 农银国际融资有限公司 CE AWL249 Bluemount Securities Limited CE BHR496
Joint Bookrunners (6)
中信建投(国际)融资有限公司 CE BAU112 农银国际融资有限公司 CE AWL249 Bluemount Securities Limited CE BHR496 Dongxing Securities (Hong Kong) Company Limited CE BBY779 HEAD & SHOULDERS SECURITIES LIMITED CE AFS455 广发证券(香港)经纪有限公司 CE AOB364
Joint Lead Managers (6)
中信建投(国际)融资有限公司 CE BAU112 农银国际证券有限公司 CE ACX411 Bluemount Securities Limited CE BHR496 Dongxing Securities (Hong Kong) Company Limited CE BBY779 HEAD & SHOULDERS SECURITIES LIMITED CE AFS455 广发证券(香港)经纪有限公司 CE AOB364

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman曹長城—
Company Secretary梁偉峰—
No director data available.

Major Shareholders

Major Shareholders & Holdings曹長城先生透過Full Bliss、Rayford及致凱持有487,200,000股,佔緊隨全球發售完成後已發行股本60.90%;Full Bliss及Rayford各持有180,180,000股(22.52%);曹篤篤先生透過致凱持有126,840,000股(15.86%);華潤醫藥基金持有60,000,000股(7.50%);第一聯雅及林曉波先生持有39,960,000股(5.00%)。
About this page

This page shows Fusen Pharm (01652) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect